Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
SY-001 by CellOrigin Technology (Hangzhou) for Solid Tumor: Likelihood of Approval
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Solid Tumor. According to GlobalData,...
Data Insights
SY-001 by CellOrigin Technology (Hangzhou) for Pancreatic Cancer: Likelihood of Approval
SY-001 is under clinical development by CellOrigin Technology (Hangzhou) and currently in Phase I for Pancreatic Cancer. According to GlobalData,...